5 results on '"Shelly McCrady-Spitzer"'
Search Results
2. At-home use of a pregnancy-specific Zone-MPC closed-loop system for pregnancies complicated by type 1 diabetes: a single arm, observational multicenter study
- Author
-
the LOIS-P Diabetes and Pregnancy Consortium, Eyal Dassau, Francis J. Doyle III, Jordan E. Pinsker, Walter K. Kremers, Isabella Zaniletti, Sunil Deshpande, Shafaq Rizvi, Corey Reid, Mari Charisse Trinidad, Selassie Ogyaadu, Shelly McCrady-Spitzer, Donna Desjardins, Mei Mei Church, Camilla M. Levister, Ravinder Jeet Kaur, Grenye O’Malley, Kristin Castorino, Basak Ozaslan, Yogish C. Kudva, and Carol J. Levy
- Abstract
OBJECTIVE: There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the United States. This study aimed to evaluate the feasibility and performance of at-home use of a zone model predictive controller based closed-loop insulin delivery system customized for pregnancies complicated by type 1 diabetes (CLC-P). RESEARCH DESIGN AND Methods: Pregnant women with type 1 diabetes using insulin pumps were enrolled in the second or early third trimester. After study sensor wear collecting run-in data on personal pump therapy and two days of supervised training, participants used CLC-P targeting 80-110 mg/dL during the day and 80-100 mg/dL overnight running on an unlocked smartphone at home. Meals and activities were unrestricted throughout the trial. The primary outcome was the continuous glucose monitoring percentage of time in the target range 63-140 mg/dL versus run-in. Results: Ten participants (HbA1c 5.8±0.6%) used the system from mean gestational age of 23.7±3.5 weeks. Mean percentage time in range increased 14.1 percentage points, equivalent to 3.4 hours per day, compared to run-in (run-in: 64.5±16.3% versus CLC-P: 78.6±9.2%, P=0.002). During CLC-P use, there was significant decrease in both time over 140 mg/dL (P=0.033) and the hypoglycemic ranges of less than 63 mg/dL and 54 mg/dL (P=0.037 for both). Nine participants exceeded consensus goals of above 70% time in range during CLC-P use. ConclusionS: The results show that the extended use of CLC-P at home until delivery is feasible. Larger, randomized studies are indicated to further evaluate system efficacy and pregnancy outcomes.
- Published
- 2023
3. Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
- Author
-
Basak Ozaslan, Carol J. Levy, Yogish C. Kudva, Jordan E. Pinsker, Grenye O'Malley, Ravinder Jeet Kaur, Kristin Castorino, Camilla Levister, Mari Charisse Trinidad, Donna Desjardins, Mei Mei Church, Mitchell Plesser, Shelly McCrady-Spitzer, Selassie Ogyaadu, Kristen Nelson, Corey Reid, Sunil Deshpande, Walter K. Kremers, Francis J. Doyle, Barak Rosenn, and Eyal Dassau
- Subjects
Adult ,Blood Glucose ,Pancreas, Artificial ,Endocrinology, Diabetes and Metabolism ,Infant ,Pilot Projects ,Original Articles ,Medical Laboratory Technology ,Diabetes Mellitus, Type 1 ,Insulin Infusion Systems ,Endocrinology ,Pregnancy ,Insulin, Regular, Human ,Feasibility Studies ,Humans ,Hypoglycemic Agents ,Insulin ,Female ,Algorithms - Abstract
OBJECTIVE: Evaluating the feasibility of closed-loop insulin delivery with a zone model predictive control (zone-MPC) algorithm designed for pregnancy complicated by type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Pregnant women with T1D from 14 to 32 weeks gestation already using continuous glucose monitor (CGM) augmented pump therapy were enrolled in a 2-day multicenter supervised outpatient study evaluating pregnancy-specific zone-MPC based closed-loop control (CLC) with the interoperable artificial pancreas system (iAPS) running on an unlocked smartphone. Meals and activities were unrestricted. The primary outcome was the CGM percentage of time between 63 and 140 mg/dL compared with participants' 1-week run-in period. Early (2-h) postprandial glucose control was also evaluated. RESULTS: Eleven participants completed the study (age: 30.6 ± 4.1 years; gestational age: 20.7 ± 3.5 weeks; weight: 76.5 ± 15.3 kg; hemoglobin A1c: 5.6% ± 0.5% at enrollment). No serious adverse events occurred. Compared with the 1-week run-in, there was an increased percentage of time in 63–140 mg/dL during supervised CLC (CLC: 81.5%, run-in: 64%, P = 0.007) with less time >140 mg/dL (CLC: 16.5%, run-in: 30.8%, P = 0.029) and time 180 mg/dL (CLC: 4.9%, run-in: 13.1%, P = 0.032). Overnight glucose control was comparable, except for less time >250 mg/dL (CLC: 0%, run-in:3.9%, P = 0.030) and lower glucose standard deviation (CLC: 23.8 mg/dL, run-in:42.8 mg/dL, P = 0.007) during CLC. CONCLUSION: In this pilot study, use of the pregnancy-specific zone-MPC was feasible in pregnant women with T1D. Although the duration of our study was short and the number of participants was small, our findings add to the limited data available on the use of CLC systems during pregnancy (NCT04492566).
- Published
- 2022
4. Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges
- Author
-
Ravinder Jeet Kaur, Sunil Deshpande, Jordan E. Pinsker, Wesley P. Gilliam, Shelly McCrady-Spitzer, Isabella Zaniletti, Donna Desjardins, Mei Mei Church, Francis J. Doyle III, Walter K. Kremers, Eyal Dassau, and Yogish C. Kudva
- Subjects
Adult ,Blood Glucose ,Cross-Over Studies ,Endocrinology, Diabetes and Metabolism ,Blood Glucose Self-Monitoring ,Original Articles ,Medical Laboratory Technology ,Endocrinology ,Diabetes Mellitus, Type 1 ,Glucose ,Insulin Infusion Systems ,Insulin, Regular, Human ,Outpatients ,Humans ,Hypoglycemic Agents ,Insulin - Abstract
BACKGROUND: Automated insulin delivery (AID) systems have not been evaluated in the context of psychological and pharmacological stress in type 1 diabetes. Our objective was to determine glycemic control and insulin use with Zone Model Predictive Control (zone-MPC) AID system enhanced for states of persistent hyperglycemia versus sensor-augmented pump (SAP) during outpatient use, including in-clinic induced stress. MATERIALS AND METHODS: Randomized, crossover, 2-week trial of zone-MPC AID versus SAP in 14 adults with type 1 diabetes. In each arm, each participant was studied in-clinic with psychological stress induction (Trier Social Stress Test [TSST] and Socially Evaluated Cold Pressor Test [SECPT]), followed by pharmacological stress induction with oral hydrocortisone (total four sessions per participant). The main outcomes were 2-week continuous glucose monitor percent time in range (TIR) 70–180 mg/dL, and glucose and insulin outcomes during and overnight following stress induction. RESULTS: During psychological stress, AID decreased glycemic variability percentage by 13.4% (P = 0.009). During pharmacological stress, including the following overnight, there were no differences in glucose outcomes and total insulin between AID and physician-assisted SAP. However, with AID total user-requested insulin was lower by 6.9 U (P = 0.01) for pharmacological stress. Stress induction was validated by changes in heart rate and salivary cortisol levels. During the 2-week AID use, TIR was 74.4% (vs. SAP 63.1%, P = 0.001) and overnight TIR was 78.3% (vs. SAP 63.1%, P = 0.004). There were no adverse events. CONCLUSIONS: Zone-MPC AID can reduce glycemic variability and the need for user-requested insulin during pharmacological stress and can improve overall glycemic outcomes. Clinical Trial Identifier NCT04142229.
- Published
- 2022
5. SAT-641 Self-Reported Psychological Stress and Glucose Variability in Type 1 Diabetes on Sensor Augmented Pump over 5 Weeks
- Author
-
Mei Mei Church, Jordan E. Pinsker, Corey Reid, Sreedhar Batthula, Prabin Thapa, Ravinder Kaur, Vikash Dadlani, Yogish C. Kudva, Eyal Dassau, Shelly McCrady Spitzer, and Walter K. Kremers
- Subjects
Type 1 diabetes ,medicine.medical_specialty ,business.industry ,Endocrinology, Diabetes and Metabolism ,Diabetes Technology ,medicine.disease ,medicine.disease_cause ,Diabetes Mellitus and Glucose Metabolism ,Internal medicine ,Cardiology ,Medicine ,Psychological stress ,business ,AcademicSubjects/MED00250 - Abstract
Introduction: Patients and their families and medical providers have assumed that psychologic stress impacts glucose control in T1D (Type 1 Diabetes) though studies providing confirmatory evidence in real world settings are, to our knowledge, lacking. We hypothesized that self-reported psychologic stress worsens glucose control in T1D. Method: We studied 20 adults with T1D on continuous glucose monitor (CGM), sensor augmented insulin pump (SAP) prospectively at 2 clinical research centers. Patients reported psychological stress through stress diaries for 5 weeks on a severity scale of 1-7 using hard copy logs including time of onset and offset of stress and severity. For analytic purpose, grades 1-4 are classified as mild and grades 5-7 as severe. Results: Baseline characteristics were age 44.9±15.0 years, F/M 12/8, HbA1c 6.8 ± 0.7%, and diabetes duration of 22.9±15.9 years. We analyzed glucose variability during days of stress versus days without stress. During a 24 hour period, patients experienced less hypoglycemia during days with stress versus days without stress (p value 0.03). During the 5 week period, patients reported 23 ± 19.5 events. We analyzed the impact of self-reported stress on CGM data streams after excluding stress events associated with missing CGM data, nocturnal events (from 12 MN to 6 AM, too few events) and events for which subjects did not provide duration of stress. Thus, we analyzed 19.5 ± 17 events per patient from 6AM to 12MN. From 6 AM to 12 MN, the episodes lasted 179 ± 255 minutes with 83 % episodes being mild/moderate and 17% moderate/ severe. Number of CGM readings during daytime stress episodes were 717± 1120 compared to 8768± 1238 during non-stress periods. Impact of stress from 6 AM to 12 MN (Mid-Night) on CGM glucose was analyzed using matched paired t test. Mean glucose (160.6±41.9 vs 148.3± 28.6) and SD (53.2 ±17.7 vs 56.1±14.6) did not show a difference; however % of time spent below 70 mg/dl was less (4 ± 5) in patients during stressful periods compared to times without stress (6.3± 5.5, P value 0.02). Conclusions: To our knowledge, this is the first study attempting to analyze the impact of self-reported stress using daily stress diaries on CGM data streams in T1D patients on SAP. The study revealed significant challenges experienced by patients in reporting adequate data. Self-reported stress was not associated with hyperglycemia. However, days of self-reported stress and periods during patients reported stress were characterized by less hypoglycemia on CGM data streams.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.